Compare iShares MBS ETF (MBB) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MBS ETF vs McKesson Corporation — how do they compare? iShares MBS ETF trades at $93.39, while McKesson Corporation trades at $832.45 (market cap $97.35B). The key difference: McKesson Corporation pays a 0.39% dividend while iShares MBS ETF pays none, and McKesson Corporation is trading nearer its 52-week high, iShares MBS ETF nearer its low. Which is the better fit depends on your goals.
| MBB | MCK | |
|---|---|---|
52-Week High | $96.91 | $995.69 |
52-Week Low | $92.92 | $659.01 |
Market Cap | — | $97.35B |
Sector | — | Health |
Enterprise Value | — | $101.98B |
Dividend Yield | — | 0.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MBB (iShares MBS ETF) trades at $93.41, down 0.39% on the day, with a bearish technical signal from moving averages and key indicators like ADX showing strong sell signals. The ETF has maintained consistent dividend payments, with recent distributions of $0.33-$0.34 per share. Institutional activity shows mixed sentiment with Comerica Bank reducing its position while Concurrent Investment Advisors and Aureum Wealth Management increased their stakes significantly.
The ETF faces headwinds from the bearish technical setup and mortgage market volatility, though consistent dividend payments provide income stability. Key risks include interest rate sensitivity and MBS market liquidity, while institutional accumulation suggests some long-term confidence in the asset class despite near-term technical weakness.
McKesson (MCK) trades at $828.84, down 1.49% on the day, with a bullish technical outlook supported by moving averages and key support at $826. The company shows strong revenue growth, reaching $359.05B in 2025, and has beaten EPS estimates for three consecutive quarters. Analyst sentiment is overwhelmingly positive with 24 buy ratings and a consensus price target of $932.83, indicating 12.5% upside potential.
The outlook for MCK remains favorable due to consistent earnings beats, robust cash flow generation, and leadership in healthcare distribution. Risks include thin profit margins (1.18% net margin) and high liabilities relative to equity. Investors should focus on execution in specialty pharma and oncology services as key growth drivers amid competitive and regulatory pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
